National Cancer Institute (NCI)
This phase II trial studies how well a vaccine called Nous-209 works in reducing the size of abnormal area of tissue growth or polyps (colorectal lesions) in patients with Lynch syndrome. When patients have Lynch syndrome, errors in the genetic information inside cells are not properly corrected. When that happens, the cells produce new proteins called neoantigens. Nous-209 is a vaccine with man-made copies of neoantigens combined with viral vectors. Neoantigens are new proteins that form inside tumor cells when certain mutations occur inside them. The body's immune system recognizes these proteins as foreign and generates a response against the tumor cell that produced the neoantigen. Giving the Nous-209 vaccine may be able to reduce the size of existing colorectal lesions (polyps) that were 5 to 15 mm in diameter at the time of patients' first colonoscopy or flexible sigmoidoscopy.
PRIMARY OBJECTIVE: I. To assess the effect of adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP and modified vaccinia Ankara virus (MVA) tumor-specific neoantigen boosting vaccine MVA-209-FSP (Nous-209) on the participant-level response rate based on the change from baseline to week 16 in the size of qualified colorectal lesions that are greater than or equal to 5 mm and less than or equal to 15 mm in diameter detected at the baseline lower gastrointestinal (GI) endoscopy (change of the cumulative size of lesions per trial participant). SECONDARY OBJECTIVES: I. To assess the…
Inclusion Criteria: * Participants must be 18 years or older * Participants must be diagnosed with Lynch syndrome. They must be documented carriers (or obligate carriers by pedigree) of a germline mutation in MMR genes (MLH1, MSH2/EPCAM, MSH6, or PMS2) that is deleterious/pathogenic or suspected to be deleterious/pathogenic (known or predicted to be detrimental/loss of function, respectively). The mutation must have been identified through a Clinical Laboratory Improvement Act (CLIA)-approved laboratory setting or an equivalent international agency. Final determination of eligibility for any…
Given IM
Undergo tissue biopsies
Undergo blood sample collection
Undergo colonoscopy
Given IM
Undergo flexible sigmoidoscopy